FDA Proposes Permanent Ban on 503B GLP-1 Compounding

The FDA proposed on April 30 to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List, a move that would permanently close large-scale compounding of these drugs by outsourcing facilities. Public comments are open until June 29, 2026.

What happened

Section 503B of the Federal Food, Drug, and Cosmetic Act allows registered outsourcing facilities to compound drugs from bulk substances — bypassing the normal FDA approval process — when specific conditions are met. One key condition: the bulk substance must appear on FDA's 503B Bulks List, meaning there's a demonstrated clinical need for the compounded version.

During the GLP-1 drug shortages of 2022–2024, both semaglutide and tirzepatide were placed on FDA's drug shortage list, which opened a parallel compounding pathway. When the shortages resolved — semaglutide removed from the shortage list in February 2025, tirzepatide before that — FDA took action to close the shortage-based pathway.

The April 30 proposal goes a step further: it formally evaluates whether semaglutide, tirzepatide, and liraglutide should ever have appeared on the 503B Bulks List in the first place. FDA's determination is that no clinical need exists for outsourcing facilities to compound these substances because FDA-approved commercial products are available and adequately supply the market.

Why it matters

The proposal, if finalized, would effectively close both legal compounding pathways that allowed industrial-scale production:

Shortage-list pathway — already closed when shortages were resolved
503B Bulks List pathway — the proposed rule would explicitly exclude all three drugs

This doesn't affect traditional 503A compounding pharmacies filling patient-specific prescriptions based on documented medical need (e.g., an allergy to a preservative in the commercial product). But the large outsourcing facilities that supplied compounded GLP-1s at scale — hundreds of thousands of prescriptions per month — would have no legal basis to continue.

Compounded GLP-1s have faced mounting safety concerns: FDA's adverse event data cited over 455 reports linked to compounded semaglutide and over 320 for compounded tirzepatide. Separately, the FDA issued a warning letter to ProRx, a 503B facility, for producing tirzepatide that was ineligible for compounding and cited unsanitary sterile production conditions.

What to watch

The public comment period closes June 29, 2026. Compounding pharmacies, patient advocates, and telehealth companies with business models built on compounded GLP-1s are expected to submit comments arguing for continued access.

FDA typically finalizes 503B Bulks List decisions within 12–18 months of a proposal, though the timeline can be longer if substantial public comments require response. A final rule excluding these drugs would take effect after a compliance deadline, likely giving existing operations time to wind down.

For patients currently using compounded semaglutide or tirzepatide from a 503B outsourcing facility, the commercial market alternatives — brand-name Ozempic, Wegovy, Mounjaro, and Zepbound — are the long-term path. Whether those are affordable and covered by insurance is a distinct question.

Sources

Compounded semaglutide safety — what the test data showed while compounding was active Compounded tirzepatide guide — what the tirzepatide compounding landscape looked like Compounded retatrutide in 2026 — the separate, murkier case for a non-approved drug